Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Stratification of Pediatric COVID-19 cases by inflammatory biomarker profiling and machine learning

Devika Subramanian, Aadith Vittala, Xinpu Chen, Christopher Julien, Sebastian Acosta, Craig Rusin, Carl Allen, Nicholas Rider, Zbigniew Starosolski, Ananth Annapragada, Sridevi Devaraj
doi: https://doi.org/10.1101/2023.04.04.23288117
Devika Subramanian
1Rice University and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: sxdevara{at}texaschildrens.org devika{at}rice.edu
Aadith Vittala
1Rice University and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xinpu Chen
2Texas Children’s Hospital/Baylor College of Medicine
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christopher Julien
2Texas Children’s Hospital/Baylor College of Medicine
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sebastian Acosta
2Texas Children’s Hospital/Baylor College of Medicine
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Craig Rusin
2Texas Children’s Hospital/Baylor College of Medicine
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carl Allen
2Texas Children’s Hospital/Baylor College of Medicine
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nicholas Rider
2Texas Children’s Hospital/Baylor College of Medicine
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zbigniew Starosolski
2Texas Children’s Hospital/Baylor College of Medicine
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ananth Annapragada
2Texas Children’s Hospital/Baylor College of Medicine
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sridevi Devaraj
2Texas Children’s Hospital/Baylor College of Medicine
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: sxdevara{at}texaschildrens.org devika{at}rice.edu
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

An objective method to identify imminent or current Multi-Inflammatory Syndrome in Children (MIS-C) infected with SARS-CoV-2 is highly desirable. The aims was to define an algorithmically interpreted novel cytokine/chemokine assay panel providing such an objective classification. This study was conducted on 4 groups of patients seen at multiple sites of Texas Children’s Hospital, Houston, TX who consented to provide blood samples to our COVID-19 Biorepository. Standard laboratory markers of inflammation and a novel cytokine/chemokine array were measured in blood samples of all patients. Group 1 consisted of 72 COVID-19, 66 MIS-C and 63 uninfected control patients seen between May 2020 and January 2021 and predominantly infected with pre-alpha variants. Group 2 consisted of 29 COVID-19 and 43 MIS-C patients seen between January-May 2021 infected predominantly with the alpha variant. Group 3 consisted of 30 COVID-19 and 32 MIS-C patients seen between August-October 2021 infected with alpha and/or delta variants. Group 4 consisted of 20 COVID-19 and 46 MIS-C patients seen between October 2021-January 2022 infected with delta and/or omicron variants. Group 1 was used to train a L1-regularized logistic regression model which was validated using 5-fold cross validation, and then separately validated against the remaining naïve groups. The area under receiver operating curve (AUROC) and F1-score were used to quantify the performance of the algorithmically interpreted cytokine/chemokine assay panel. Standard laboratory markers predict MIS-C with a 5-fold cross-validated AUROC of 0.86 ± 0.05 and an F1 score of 0.78 ± 0.07, while the cytokine/chemokine panel predicted MIS-C with a 5-fold cross-validated AUROC of 0.95 ± 0.02 and an F1 score of 0.91 ± 0.04, with only sixteen of the forty-five cytokines/chemokines sufficient to achieve this performance. Tested on Group 2 the cytokine/chemokine panel yielded AUROC =0.98, F1=0.93, on Group 3 it yielded AUROC=0.89, F1 = 0.89, and on Group 4 AUROC= 0.99, F1= 0.97). Adding standard laboratory markers to the cytokine/chemokine panel did not improve performance. A top-10 subset of these 16 cytokines achieves equivalent performance on the validation data sets. Our findings demonstrate that a sixteen-cytokine/chemokine panel as well as the top ten subset provides a sensitive, specific method to identify MIS-C in patients infected with SARS-CoV-2 of all the major variants identified to date.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

NIH R61-HD 105593

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

IRB Committee of Baylor College of Medicine gave ethical approval of this work

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

Data Availability

All data produced in the present study are available upon reasonable request to the authors

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted April 04, 2023.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Stratification of Pediatric COVID-19 cases by inflammatory biomarker profiling and machine learning
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Stratification of Pediatric COVID-19 cases by inflammatory biomarker profiling and machine learning
Devika Subramanian, Aadith Vittala, Xinpu Chen, Christopher Julien, Sebastian Acosta, Craig Rusin, Carl Allen, Nicholas Rider, Zbigniew Starosolski, Ananth Annapragada, Sridevi Devaraj
medRxiv 2023.04.04.23288117; doi: https://doi.org/10.1101/2023.04.04.23288117
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Stratification of Pediatric COVID-19 cases by inflammatory biomarker profiling and machine learning
Devika Subramanian, Aadith Vittala, Xinpu Chen, Christopher Julien, Sebastian Acosta, Craig Rusin, Carl Allen, Nicholas Rider, Zbigniew Starosolski, Ananth Annapragada, Sridevi Devaraj
medRxiv 2023.04.04.23288117; doi: https://doi.org/10.1101/2023.04.04.23288117

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Pediatrics
Subject Areas
All Articles
  • Addiction Medicine (427)
  • Allergy and Immunology (753)
  • Anesthesia (220)
  • Cardiovascular Medicine (3281)
  • Dentistry and Oral Medicine (362)
  • Dermatology (274)
  • Emergency Medicine (478)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1164)
  • Epidemiology (13341)
  • Forensic Medicine (19)
  • Gastroenterology (897)
  • Genetic and Genomic Medicine (5132)
  • Geriatric Medicine (479)
  • Health Economics (781)
  • Health Informatics (3254)
  • Health Policy (1138)
  • Health Systems and Quality Improvement (1189)
  • Hematology (427)
  • HIV/AIDS (1014)
  • Infectious Diseases (except HIV/AIDS) (14613)
  • Intensive Care and Critical Care Medicine (910)
  • Medical Education (475)
  • Medical Ethics (126)
  • Nephrology (522)
  • Neurology (4905)
  • Nursing (261)
  • Nutrition (725)
  • Obstetrics and Gynecology (880)
  • Occupational and Environmental Health (795)
  • Oncology (2516)
  • Ophthalmology (722)
  • Orthopedics (280)
  • Otolaryngology (346)
  • Pain Medicine (323)
  • Palliative Medicine (90)
  • Pathology (540)
  • Pediatrics (1298)
  • Pharmacology and Therapeutics (548)
  • Primary Care Research (554)
  • Psychiatry and Clinical Psychology (4194)
  • Public and Global Health (7483)
  • Radiology and Imaging (1702)
  • Rehabilitation Medicine and Physical Therapy (1010)
  • Respiratory Medicine (979)
  • Rheumatology (478)
  • Sexual and Reproductive Health (495)
  • Sports Medicine (424)
  • Surgery (546)
  • Toxicology (71)
  • Transplantation (235)
  • Urology (203)